AZ funded Non clinical PhD Studentship (Fixed Term)

Applications are invited for 4-year PhD studentship based in the Department of Pharmacology, University of Cambridge and the new AstraZeneca Discovery Centre at Cambridge conducting research into how the microbiome contributes to chronic pain. The project will be jointly supervised by Dr David Bulmer (Cambridge) and Dr Fraser Welsh (AstraZeneca) and will provide the student with an opportunity to work across both sites, in addition to the broader multidisciplinary team of clinicians and academics investigating the microbiome and pain at the University and Medical School.

We have recently identified a pathogenic microbial signature which markedly deviates from household controls in people with chronic abdominal pain that can be corrected by dietary intervention. Metagenomic and metabolomic analysis supports a causative role for bacterial metabolites, which we will seek to evaluate in this studentship using functional assays of pain signalling, neuroepithelial and immune cell function, in conventional, and germ-free animals to recapitulate the dysbiotic microbial phenotype.

This PhD builds on a body of translational work from the Bulmer lab (Bautzova et al (2018) Sci Signal. 11(561); Higham et al (2024) Pain 165 (7): 1592-1604) and will utilise ex-vivo electrophysiological studies and Ca2+ imaging from mouse and human nociceptors.

Applicants must have or expect to obtain at least an upper 2nd class honours science degree (or equivalent), be highly motivated, capable of developing their own ideas, and keen to interact effectively with other lab members.

Your online application will need to include: -Two academic references - Transcript - CV/resume - Evidence of competence in English If required - you can check using our tool - Statement of interest (no more than 300 words)

The studentship comes with a stipend of £21,500 per annum and covers the University Composition Fee at the home student rate with effect from 1 October 2025.